Clinical trial
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients…
NCT00107315 · Roswell Park Cancer Institute, Other · Terminated
Key facts
| NCT number | NCT00107315 |
|---|---|
| Title | Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer |
| Official title | A Phase II Study of Capecitabine and Bevacizumab in Elderly Patients With Metastatic Colorectal Cancer |
| Lead sponsor | Roswell Park Cancer Institute, Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer |
| Intervention type | Biological, Drug |
| Interventions | bevacizumab, capecitabine |
| Enrollment | 16 |
| Start date | Jul 1, 2004 |
| Primary completion | Jun 1, 2008 |
| First posted | Apr 6, 2005 |
| Last update posted | Jul 4, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: